| INTRODUC TI ON
Mesenchymal stem cells (MSCs) represent one type of stem/progenitor cell-based therapies used to treat ischaemic diseases, such as stroke, cardiovascular disease, peripheral arterial disease, and ischaemic kidney disease. 1 Since these cells have a self-renewal ability, multi-differentiation potential, and an immunomodulatory effect, various studies have investigated the potential benefit of MSC-based therapies in pre-clinical and clinical trials. 1, 2 Unfortunately, transplanted MSCs have shown a low survival rate in ischaemic-damaged tissue because a sudden or prolonged blockage of blood flow induces hypoxia, oxidative stress, endoplasmic reticulum (ER) stress and nutrient deprivation. 3, 4 To improve the therapeutic efficacy of MSC-based therapies in pathophysiological conditions, a number of different approaches have been explored, including preconditioning, genetic modification, co-transplantation of MSCs with other supporting cells, administration of MSCs along with medication and application of the MSCs with biomaterials. 5 Although these strategies have improved the functionalities of MSCs, it is important to understand the underlying mechanisms behind these strategies in order to safely use MSC-based therapies in ischaemic diseases. The ER is an important organelle for protein folding, calcium homoeostasis, and lipid and carbohydrate metabolism. 6 Endoplasmic reticulum stress occurs in response to a range of cellular stresses, such as ischaemic damage, redox imbalance, oxygen and glucose deprivation and perturbations in calcium homoeostasis. 6, 7 To maintain cellular homoeostasis against ER stress, cells have well-orchestrated processes, including ER-assisted degradation, autophagy, the hypoxia response and mitochondrial biogenesis. 6, 8 Among these processes, autophagy plays a pivotal role in cell survival, cell growth, energy metabolism and lifespan in several cellular stresses under physiological conditions. 6, 8 However, under pathophysiological conditions, severe stress induces excessive autophagy, causing cell death. 9 Therefore, in order to create a successful cell-based therapy for ischaemic diseases, the key is to inhibit the excessive autophagy without eliminating the basal autophagy level.
The normal cellular prion protein (PrP C ) is encoded by the Prnp gene, which plays a physiological role in various cells. 10 Accumulating evidence indicates roles for PrP C in a wide range of cellular processes, such as stress protection, oxidative stress-induced apoptosis, the ER-stress response, cellular differentiation, the immune system, mitochondrial homoeostasis, and metal ion homoeostasis.
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Knockout of the Prnp gene induces a dysfunction in synaptic transmission and plasticity, memory formation, calcium homoeostasis, neurite outgrowth and metabolism. 10 In stem cell biology, PrP C is essential for cell proliferation, differentiation and self-renewal. [12] [13] [14] In addition, our previous studies have shown that PrP C is up-regulated by hypoxia preconditioning and melatonin treatment, and that transplanted MSCs facilitate neovascularization in a murine hindlimb ischaemia model. 15, 16 Moreover, augmentation of PrP C expression by treatment of MSCs with tauroursodeoxycholic acid inhibited ER stress-mediated cell death. 17 Therefore, an understanding of the role of PrP C may provide insights into the development of stem/progenitor cell-based therapies.
Melatonin, N-acetyl-5-methoxytryptamine, is an indoleamine containing hormone secreted by several tissues including the bone marrow, ovary, testes, gut, placenta and liver, as well as the pineal gland. 18, 19 Melatonin has a variety of functions, including the regulation of sleep and circadian rhythms, as well as having anti-inflammatory, antioxidant and anti-cancer effects. [20] [21] [22] [23] Numerous studies have shown that melatonin-treated MSCs can facilitate a therapeutically functional recovery in myocardial infarction, skin wounds, lung ischaemia-reperfusion injury and sepsis-induced kidney injury. [24] [25] [26] [27] In addition, our previous study has shown that melatonin-treated
MSCs enhance neovascularization in hindlimb ischaemia through PrP C expression. 16 This study, as an extension of this research, focuses on the effect of melatonin on ER stress in ischaemic disease.
We show here that melatonin protects against autophagy-mediated apoptosis both in vitro and in vivo following ischaemic-induced ER stress and this occurs through the upregulation of PrP C expression.
In addition, we demonstrate the therapeutic effect of melatonintreated MSCs on neovascularization in a murine hindlimb ischaemia model. 
| MATERIAL AND ME THODS

| Cell culture
| Chemical treatment of MSCs
Mesenchymal stem cells were washed twice with phosphate-buff- 
| Animal care procedures and experiments
The Institutional Animal Care and Use Committee of Soonchunhyang University approved all surgical interventions and post-operative animal care (IACIC2013-5), and these were performed in accordance with the National Research Council Guidelines for the Care and
Use of Laboratory Animals. Animal experiments were performed on 8-week-old male Balb/C nude mice (Biogenomics, Seoul, Korea), which were maintained in a pathogen-free facility under a 12-hours light/dark cycle at 25°C with free access to water and regular laboratory chow in accordance with the regulations of Soonchunhyang University, Seoul Hospital.
| Murine hindlimb ischaemia model
Experiments using a murine hindlimb ischaemia model were performed as previously reported with minor modifications. 15, 28 
| Statistical analysis
All data are expressed as the mean ± SE of the mean (SEM) and all of the experiments were analysed using a one-way analysis of variance (ANOVA). Some comparisons of ≥3 groups were made using the Bonferroni-Dunn test. A P value <0.05 was considered statistically significant. These data were statistically analysed using SigmaPlot (Systat Software, San Jose, CA, USA).
Detailed some methods are provided in Appendix .
| RE SULTS
| Ischaemia-mediated ROS induces apoptosis through ER stress in MSCs and in hindlimb ischaemicinjured tissues
ROS is one of the inducers of ER stress which is known to be involved in cell life and death. 29 Our previous study demonstrated that ischaemia-induced ROS-mediated ER stress-triggered apoptosis in ischaemic tissues and led to a deterioration in the quality and efficacy of the transplanted MSCs used as a cell-based therapy for ischaemic diseases. 17 To further investigate the effect of ROS on ER stress in MSCs and ischaemic tissues, the activation and expression of ER stress-as- In addition, the activation and expression of these proteins were also increased in ischaemic-injured tissues ( Figure 1E-H 
| ROS-mediated ER stress activates autophagy in both MSCs and hindlimb ischaemic-injured tissues
Under physiological conditions, ER stress induces autophagy in order to remove misfolded proteins, resulting in the inhibition of cell death; however, under pathophysiological conditions, severe autophagy leads to cell death. 30 To evaluate the effect of ROS-mediated ER stress on autophagy in MSCs, the expression of autophagy marker proteins was examined after treatment of (Figure 2A,B) . In addition, ROS-mediated ER stress increased the expression of another autophagy marker, ATG7, as well as LC3B and Beclin-1, and decreased the level of p62, which is known to be decreased following autophagy 31 ( Figure 2C ,D).
These findings indicate that autophagy is activated following ROS-mediated ER stress. To further examine the effect of ischaemic-induced ER stress on autophagy in ischaemic-injured tissues, the expression of LC3B, Beclin-1, and ATG7 were increased and the level of p62 was decreased ( Figure 2E ,F). In addition, immunofluorescence staining for LC3 showed that the level of LC3 was significantly increased in ischaemic tissue, compared with that in normal tissue ( Figure 2G ,H). Taken together, these results suggest that ischaemia-induced ER stress activates the autophagy process.
| Melatonin protects cells from oxidative stress through the melatonin-MT 2 -PrP C axis
Our previous study demonstrated that melatonin enhances MSC bioactivities, including proliferation, anti-oxidative effects and immunomodulatory effects, through the upregulation of PrP 
| Melatonin-treated MSCs enhance neovascularization in a murine hindlimb ischaemia model
To examine whether melatonin-treated MSCs could promote the formation of neovessels in a murine hindlimb ischaemia model, blood perfusion and tissue recovery were assessed following transplantation of MSCs into the ischaemic-injured tissue. To stimulate the transplanted MSCs over the long-term, an intraperitoneal injection of melatonin was performed every day for 28 days following surgery. The blood perfusion ratio was analysed using LDPI at postoperative day 0, 3, 7, 14, 21 and 28. The blood perfusion ratio was significantly higher in limbs transplanted and maintained with the The levels of LC3BII were normalized to LC3B1 whereas the levels of Beclin-1, p62, and ATG7 were normalized to β-actin. Values represent the mean ± SEM. *P < 0.05; **P < 0.01 vs untreated MSCs. E, Western blot of LC3B, Beclin-1, p62, and ATG7 in ischaemic-injured tissues from the murine hindlimb ischaemia model, 4, 12 and 24 hours after surgery. F, The levels of LC3BII were normalized to LC3B1 whereas the levels of Beclin-1, p62 and ATG7 were normalized to α-tubulin. Values represent the mean ± SEM. *P < 0.05; **P < 0.01 vs normal tissue. G, Immunofluorescent staining for DAPI (blue) and LC3B (green) in normal and ischaemic tissues. Figure 6F -H); this effect also led to the increased apoptosis in ischaemic-injured tissues (see, Figure 6I ,J).
In addition, oxidative stress increased the expression PrP C (see, Figure 3A ). Therefore, PRNP siRNA might suppress the physiological 
| D ISCUSS I ON
Ischaemic-injured sites have harsh tissue conditions, including low oxygen levels, restricted nutrients, and high levels of ROS, with the result that effectiveness of the transplanted stem/progenitor cells used for regenerative medicine to treat ischaemic diseases is decreased. Among the pathophysiological conditions, ischaemia/ROSinduced ER stress is known to induce apoptotic cell death in host tissues as well as in the transplanted stem/progenitor cells. 6, 7, 17, 29 To solve this issue, several studies have suggested that melatonin could be used to protect against ER stress in neurotoxic states, liver diseases, immunotoxic states, pulmonary fibrosis and diabetes. 33 Our previous study revealed that melatonin could enhance MSC functionality for the treatment of ischaemic disease by upregulating the express of PrP C . 16 To further examine whether melatonin protects against ER stress through the upregulation of PrP C , we have confirmed the protective effect of melatonin on autophagy-mediated cell death in MSCs with ischaemia-induced ER stress. Our results showed that melatonin-induced PrP C expression decreased ER stress/autophagy-mediated apoptosis both in vitro and in a murine hindlimb ischaemia model.
Various reports have indicated that PrP C , which is expressed in many cells beyond the central nerve system, 34 contributes to the regulation of several cellular process, including differentiation, proliferation, stress protection, myelin maintenance, mitochondrial homoeostasis and interaction with signal transduction pathways. 11, 35 In particular, PrP C has been shown to have a protective effect against ROS-mediated oxidative stress. 11 PrP C suppresses ROS production by regulating the activities of superoxide dismutase and glutathione peroxidase. 36, 37 In fact, our previous study revealed that TUDCA-induced PrP C increased MnSOD expression via phosphorylation of Akt and activation of its signalling pathway. 17 In keeping with the concept of PrP C regulating the activity of enzymes that control ROS levels it has been shown in a PrP-null mouse, that total SOD activity was significantly decreased through modulation of mitochondrial complex I. 38 Since ischaemic-injured tissues represent a ROS-rich oxidative stress environment, reductions in ROS levels are important for the successful transplantation of stem/progenitor cells in cell-based therapies. One study has shown that PrP C enhances MSC engraftment to bone marrow. 39 Hypoxia-induced PrP C expression has also been shown to facilitate the survival of transplanted MSCs at ischaemic-damaged sites in hindlimb model of ischaemia. 15 Our data indicated that melatonin increased the activa- Melatonin is known to be a powerful ROS scavenger through this regulation of antioxidant enzymes. 40, 41 Several studies have investigated the protective effect of melatonin in MSCs with ischaemic injury in order to increase their efficacy in transplantation.
In small bowel ischaemia-reperfusion injury, injection with melatonin, along with adipose-derived MSCs, decreased ischaemic damage through the regulation of antioxidant enzymes, notably NAD(P)H dehydrogenase, glutathione reductase and glutathione peroxidase. 42 In addition, melatonin blocked oxidative stress-induced premature senescence and promoted the therapeutic efficacy of MSCs in a murine myocardial infarction model via a sirtuin-1-dependent mechanism. 24, 43 Our results therefore confirmed that melatonin stimulation of MSCs enhances the functional recovery and neovascularization in a murine hindlimb ischaemia model via PrP C expression. Consistent with these results, our previous studies have shown that PrP C is a key molecule in regulating the functionality and therapeutic potential of MSCs in ischaemic diseases. [15] [16] [17] Taken together, our data show /L) . B, The levels of p-PERK, p-eIF2α and ATF4 were normalized to those of PERK, eIF2α and β-actin, respectively. Values represent the mean ± SEM. *P < 0.05; **P < 0.01 vs untreated MSCs, ## P < 0.01 vs MSCs treated with H 2 O 2 , $$ P < 0.01 vs MSCs treated with melatonin, and && P < 0.01 vs MSCs treated with melatonin and si-PRNP. C, Western blot of p-IRE1α, IRE1α, p-JNK, JNK, p-p38, p38 and CHOP after treatment of melatonin-pretreated MSCs with hydrogen peroxide (200 μmol/L). D, The levels of p-IRE1α, p-JNK, p-p38 and CHOP were normalized to those of IRE1α, JNK, p38 and β-actin, respectively. Values represent the mean ± SEM. *P < 0.05; **P < 0.01 vs untreated MSCs, ## P < 0.01 vs MSCs treated with H 2 O 2 , $$ P < 0.01 vs MSCs treated with melatonin, and && P < 0.01 vs MSCs treated with melatonin and si-PRNP. E, Western blot of p-PERK, PERK, p-eIF2α, eIF2α and ATF4 in ischaemic-injured tissues 1 days after injection with PBS, MSCs (MSC), MSCs treated with melatonin (MSC + Melatonin), MSCs treated with melatonin and PRNP siRNA (MSC + si-PRNP + Melatonin), or MSCs treated with melatonin and scrambled siRNA (MSC + si-Scr + Melatonin) in a murine hindlimb ischaemia model. F, The expressions of p-PERK, p-eIF2α and ATF4 were normalized to those of PERK, eIF2α, and α-tubulin, respectively. Values represent the mean ± SEM. *P < 0.05; **P < 0.01 vs normal, ## P < 0.01 vs PBS, $ P < 0.05; $$ P < 0.01 vs MSC, and && P < 0.01 vs MSC + si-PRNP + Melatonin. G, Western blot of p-IRE1α, IRE1α, p-JNK, JNK, p-p38, p38 and CHOP in the same tissues as in E. H, The expression levels of p-IRE1α, p-JNK, p-p38 and CHOP were normalized to those of IRE1α, JNK, p38 and α-tubulin, respectively. Values represent the mean ± SEM. *P < 0.05; **P < 0.01 vs normal, # P < 0.05; ## P < 0.01 vs PBS, $ P < 0.05; $$ P < 0.01 vs MSC, and && P < 0.01 vs MSC + si-PRNP + Melatonin that melatonin protects against ROS-mediated oxidative stress by regulating PrP C -dependent antioxidant enzyme activity.
This study also showed that ROS/ischaemia triggered the activation of ER stress-associated proteins in both MSCs in vitro, and in ischaemic-injured tissues in vivo. Prolonged activation of PERK and IRE1α induce apoptotic cell death under pathophysiological conditions. 44 In addition to activation of the unfolded protein response ER stress stimulates autophagy. Autophagy is cellular 16 In the liver of leptin-deficient mice, melatonin has also F I G U R E 7 Assessment of functional recovery and neovascularization in a murine hindlimb ischaemia model. A, Blood perfusion was assessed using laser Doppler perfusion imaging analysis in the ischaemic limbs of mice injected with PBS, MSCs (MSC), melatonin-treated MSCs (MSC + Melatonin), MSCs treated with melatonin and PRNP siRNA (MSC + si-PRNP + Melatonin), or MSCs treated with melatonin and scrambled siRNA (MSC + Scr-siRNA + Melatonin). B, The blood perfusion ratio was measured by LPDI analysis (blood flow in the left ischaemic limb/blood flow in the right non-ischaemic limb). Values represent the mean ± SEM. *P < 0.05; **P < 0.01 vs PBS, and ## P < 0.01 vs MSC. C, Distribution of the different outcomes (limb salvage, toe loss and foot necrosis) in each of the treatment groups at post-operative day 28. D, Secretion of human VEGF, HGF and FGF from the ischaemic-injured tissues in each group was assessed by ELISA. Values represent the mean ± SEM. **P < 0.01 vs normal, ## P < 0.01 vs PBS, $$ P < 0.01 vs MSC, and && P < 0.01 vs MSC + si-PRNP + Melatonin. E-G At post-operative day 28, the formation of capillaries and arterioles were analysed using immunofluorescent staining for CD31 (green; scale bar = 50 μm; E) and α-SMA (red; scale bar = 100 μm; G). The capillary (F) and arteriole (H) densities were quantified as the number of CD31-positive cells and α-SMA-positive cells, respectively. Values represent the mean ± SEM. *P < 0.05; **P < 0.01 vs PBS, # P < 0.05; ## P < 0.01 vs MSC, $$ P < 0.01 vs MSC+si-PRNP + Melatonin 
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